Lushang Health Industry Development Co.,Ltd.: history, ownership, mission, how it works & makes money

Lushang Health Industry Development Co., Ltd., founded in 1993 in Jinan and now trading on the Shanghai Stock Exchange as 600223, has evolved from a real estate origin into a focused pharmaceutical subsidiary of Shandong Freda Biological Co., Ltd., rebranding in June 2019 toward health and again in April 2023 as Lushang Freda Pharmaceutical Co., Ltd.; today the company employs approximately 3,630 people and runs a vertically integrated model-R&D, manufacturing and nationwide distribution-serving hospitals, pharmacies and chain drugstores while investing heavily in innovation with roughly RMB 200 million in R&D last fiscal year (up 15% year-on-year); its diversified revenue streams include domestic product sales, raw materials and additives, international sales that accounted for 30% of total revenue in 2023, and a strong e-commerce presence (online channels were 40% of sales in 2023), supported by strategic acquisitions such as a RMB 150 million purchase expected to add about RMB 50 million in revenue, and the company holds a market capitalization near CNY 7.99 billion as of December 2025.

Lushang Health Industry Development Co.,Ltd. (600223.SS): Intro

• Founded: 1993 (original focus: real estate development in China)
• Rebrand to health focus: June 2019 - renamed Lushang Health Industry Development Co., Ltd.
• Further rebrand to pharmaceutical focus: April 2023 - renamed Lushang Freda Pharmaceutical Co., Ltd.
• Headquarters: Jinan, Shandong, China
• Parent / majority affiliation: Subsidiary of Shandong Freda Biological Co., Ltd.
• Stock listing: Shanghai Stock Exchange, ticker 600223.SS
• Employees: ~3,630 (as of December 2025)

• R&D and product development: formulation and clinical/preclinical work for pharmaceutical products and health-related biologics, leveraging parent-group biotech capabilities.
• Manufacturing: production of pharmaceutical formulations and possibly health products in GMP-compliant facilities (company focus shifted to ensure regulatory-compliant manufacturing).
• Distribution and sales: channel sales through hospitals, pharmacies, distributors and B2B procurement for institutional buyers.
• Licensing and partnerships: technology transfer, licensing of IP, and joint ventures to expand therapeutic/OTC portfolios and market reach.
• Service & asset monetization: leasing, asset sales or disposal of legacy real-estate holdings where applicable during transformation.

• Product sales: primary revenue from prescription drugs, OTC health products, and biologics manufactured and sold domestically.
• Contract manufacturing & OEM: revenues from third-party manufacturing and toll-processing agreements with other pharma/health firms.
• Licensing & royalties: income from out-licensing compounds, formulations, or proprietary processes.
• Institutional sales & tenders: bulk sales to hospitals, government tenders and large healthcare purchasers.
• One-off asset gains: occasional income from disposal of legacy non-core real-estate or property assets as part of strategic pivot.

• Integration with Shandong Freda Biological: access to biological R&D, manufacturing know-how and joint commercialization channels.
• Regulatory compliance and GMP scale-up: investments to meet China NMPA/GMP requirements for pharmaceutical production and clinical filings.
• Portfolio shift: moving corporate resources from property assets toward high-margin pharmaceutical products and recurring healthcare revenue streams.

Lushang Health Industry Development Co.,Ltd. (600223.SS): History

• Subsidiary relationship: Lushang Freda Pharmaceutical Co., Ltd. operates as a subsidiary of Shandong Freda Biological Co., Ltd., positioning the company within a broader industrial group with upstream biological capabilities.
• Public listing: Shares are publicly traded on the Shanghai Stock Exchange (600223.SS), providing liquidity for investors and disclosure under SSE rules.
• Shareholder base: A mix of institutional and retail investors holds the company's free float; the group parent is the largest controlling shareholder.
• Corporate governance: Governed by a board of directors and executive management team responsible for strategic direction, compliance and capital allocation.
• Investor participation: Shareholders gain exposure to growth via dividend distributions and potential capital appreciation in line with company performance and market valuation.

• How it makes money: core revenue streams include sale of finished pharmaceutical products, licensing/R&D collaborations, bulk biological intermediates supplied by group affiliates, and downstream distribution/health service activities.
• Operational model: leveraging group vertical integration - in-house biological inputs (via Shandong Freda), contract manufacturing, and a sales network - to control margins and accelerate product commercialization.
• Regulatory & transparency framework: as an SSE-listed entity, the company publishes annual and interim reports, adheres to disclosure rules and subjects major transactions to shareholder and board oversight.

Lushang Health Industry Development Co.,Ltd. (600223.SS): Ownership Structure

• Mission: Provide high‑quality pharmaceutical and healthcare products across dermatology, orthopedics, ophthalmology, gynecology and pediatrics.
• R&D commitment: Invested approximately RMB 200,000,000 in the latest fiscal year-about a 15% increase year‑on‑year.
• Values: Emphasis on innovation, integrity, regulatory compliance and improving patient quality of life.
• Patient focus: Prioritizes product development addressing diverse medical needs and enhanced patient care.

• Revenue streams:
  • Prescription pharmaceuticals sold to hospitals and clinics.
  • Over‑the‑counter and consumer healthcare products.
  • Contract manufacturing/OEM services for third parties.
  • Exports and distribution in select international markets.
  • Licensing and collaborative R&D partnerships.
• How it makes money: combination of product sales (hospital tenders, retail channels), contract manufacturing margins, and milestone/license fees from partners.
• Key metric snapshot:
  • Latest fiscal year R&D spend: RMB 200,000,000
  • R&D spend growth: +15% YoY
  • Core therapeutic areas: Dermatology, Orthopedics, Ophthalmology, Gynecology, Pediatrics

Lushang Health Industry Development Co.,Ltd. (600223.SS): Mission and Values

• Research & Development: A sustained pipeline spanning dermatology, orthopedics, ophthalmology, gynecology and pediatrics, with projects ranging from generic drug lifecycle extensions to specialty formulations and topical/ophthalmic innovations.
• Manufacturing: In-house GMP-compliant facilities equipped for tablets, capsules, sterile ophthalmic/ophthalmologic preparations, topical formulations and sterile injectables, enabling tight quality control and cost management.
• Distribution & Sales: A multi-channel commercial network that supplies tertiary and secondary hospitals, primary medical institutions, chain pharmacies and independent drugstores across provincial markets in China.
• Collaborations: Strategic engagement with hospitals, KOLs, provincial health authorities and third‑party contract research/manufacturing organizations to validate clinical utility and meet regulatory standards.
• Continuous Improvement: Ongoing investments in quality systems, regulatory affairs and process R&D to shorten time-to-market and maintain product efficacy and safety.

• Therapeutic focus areas: dermatology, orthopedics, ophthalmology, gynecology, pediatrics - each supported by dedicated product lines and targeted sales teams.
• Customer channels: Hospitals (including county and city-level), primary care institutions, retail pharmacy chains and distributors covering urban and regional markets.
• Regulatory compliance: Active maintenance of provincial and national drug approvals, pharmacovigilance programs and periodic quality audits.

• Product sales: Branded generics, specialty formulations and hospital-supplied medications are the primary revenue source, sold through tender, hospital procurement and retail channels.
• Institutional contracts: Long-term supply agreements with hospitals and regional health authorities for staple therapeutic categories (e.g., dermatology and orthopedics).
• Pipeline commercialization: Launches of improved formulations and specialty ophthalmic or topical products that command premium pricing relative to simple generics.
• Contract manufacturing and licensing: Fee-for-service manufacturing, and selective licensing partnerships for technology or compound rights.

• Focus: Incremental innovation (improved formulations, delivery systems) and clinical evidence generation in priority areas to differentiate from commodity generics.
• Resourcing: Central R&D teams plus collaborations with external CROs and academic institutions to accelerate clinical trials and regulatory filings.
• Outcomes: Product registration, hospital inclusion on formularies, and payer/tender competitiveness to drive adoption and margins.

• GMP and quality systems to meet provincial and national inspections and support market access.
• Active pharmacovigilance and post‑market surveillance to maintain safety profiles and regulatory standing.
• Engagement with healthcare professionals and KOLs for clinical validation and real-world evidence generation.

Lushang Health Industry Development Co.,Ltd. (600223.SS): How It Works

• Core products: prescription and OTC drugs, health supplements, specialty additives and raw materials sold to third‑party manufacturers.
• Therapeutic coverage: dermatology, orthopedics, ophthalmology, gynecology and pediatrics.
• Manufacturing: in‑house production facilities for finished dosage forms and active/additive ingredients to capture manufacturing margin and ensure quality control.
• R&D: focused pipelines for specialty formulations and formulation improvements to extend product lifecycle and support higher ASPs (average selling prices).
• Sales & distribution: direct sales force, hospital and pharmacy channels, distributor partnerships, e‑commerce platforms and cross‑border export networks.

• Finished pharmaceutical product sales (branded Rx/OTC and supplements) - primary revenue driver.
• Sale of raw materials and pharmaceutical additives to external manufacturers - margins from bulk sales and long‑term supply contracts.
• Online/e‑commerce sales - direct‑to‑consumer channels and third‑party platforms boosting gross margin and data capture for marketing.
• International sales - exports and overseas distribution agreements; reported to account for 30% of total revenue in 2023.
• M&A and business development - acquisitions expanding product mix and near‑term revenue contributions (e.g., RMB 150 million acquisition noted below).

• Manufacturing integration reduces COGS for finished products and allows capture of upstream margins on additives/raw materials.
• Direct e‑commerce sales improve gross margin versus wholesale by removing distributor markups; online contributed ~40% of sales in 2023.
• Export sales often carry higher ASPs or are supplemented by license/royalty arrangements in some markets.
• Acquisitions (RMB 150m deal) accelerate topline growth and bring cross‑sell opportunities; expected to add ~RMB 50m revenue in the following year, with incremental synergies over time.
• Working capital management: inventory of raw materials vs. finished goods and trade receivables from distributors are principal drivers of cash conversion cycle.

• Hospital and retail pharmacy penetration via sales teams and distributor networks for prescription and OTC products.
• Direct‑to‑consumer digital marketing and platform management for supplements and consumer health brands.
• Export channels: regional distributors, local registrations, and B2B supply agreements for raw materials.

• Expand online presence and digital marketing to grow the 40% e‑commerce contribution further.
• International market expansion to increase the 30% export share with targeted registrations and partnerships.
• Further M&A to acquire niche product lines and manufacturing capacity - building on the RMB 150m acquisition that is projected to add ~RMB 50m revenue.
• R&D investments to develop higher‑margin specialty formulations and extend exclusivity of key products.

Lushang Health Industry Development Co.,Ltd. (600223.SS): How It Makes Money

• Core product sales (prescription drugs, OTC, health supplements)
• Contract manufacturing and bulk API supply to regional and national peers
• Domestic distribution and hospital procurement contracts
• Licensing, co-development and royalties from specialty medicines
• Online direct-to-consumer sales and e-commerce platform partnerships
• Export sales targeting increased share in Southeast Asia and other markets

• Margin drivers: higher-margin specialty drugs, improved production efficiencies, and digital-channel sales mix.
• Competitive pressures from national and regional players require ongoing R&D investment and strategic partnerships.
• Digital strategy: scale online sales to represent a larger portion of total revenue via proprietary e-commerce and third-party platforms.